Clinical Trials

40 enrolled

Breast Cancer Metastatic

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

10 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

30 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT07428044 2026-02-23

HERCULES

14 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06085755 2025-12-15

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Phase 1/2 Recruiting

61 enrolled

Stomach Neoplasms

NCT06630130 2025-12-15

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

50 enrolled

Stomach Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT05982678 2025-11-26

ANISE

72 enrolled

HER2-positive Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT07180264 2025-11-18

Trastuzumab Deruxtecan in Advanced Breast Cancer

Recruiting

118 enrolled

Advanced Breast Cancer

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

88 enrolled

Breast Neoplasms

NCT06533826 2025-10-24

TRADE DXd

357 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT07134153 2025-08-21

INOVATE

Phase 1/2 Recruiting

139 enrolled

Breast Neoplasms

NCT06172127 2025-07-29

DEMETHER

165 enrolled

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT07030569 2025-06-22

RADIOSPHER2

Recruiting

500 enrolled

Breast Neoplasms

NCT06643585 2025-05-02

SURVIVE HERoes

Phase 3 Recruiting

180 enrolled

Breast Neoplasms

NCT06551220 2024-12-04

HEROIC

Recruiting

800 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT05034887 2024-11-19

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

64 enrolled

Gastric Adenocarcinoma

NCT05965479 2024-11-12

DECIPHER

25 enrolled

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Breast Neoplasms

NCT06328387 2024-03-25

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Phase 1/2 Recruiting

120 enrolled